Taken together, these findings raise the possibility that individuals vaccinated with BCG present a pre-existing pool of cross-reactive CD8 T cells, which can be recruited during SARS-CoV-2 natural infection or COVID-19 vaccine, resulting in an enhanced cellular immunity. This evidence concerns the gene CD8A and COVID-19.